As capital crowds into AI compute and defence, a tidy contrarian instinct has surfaced: people will always eat, drink, medicate and clothe themselves, so the unloved "human basics" complex must be structurally cheap. The instinct points in a defensible direction. The trouble is the vehicle. This analysis argues that owning the staples index—or the cheap mid-tier branded company that screens well—captures almost none of the return, and that the real money sits in a handful of specific nodes plus a disciplined list of things to refuse to own.
~10–15× today → 13–17×
Scale grocers with proprietary basket data and disclosed retail media are the strongest long, but the re-rate is capped by margin-cap politics. In a 150–250bp real-yield decline, more than half the move is duration rather than idiosyncratic operating improvement.
~26% / 31% / 37%
GLP-1 discontinuation at three, six and twelve months. Persistence is not improving. The oral wave is steeper because price and access collapsed, not because people stay on the drugs longer: this is a broad, shallow, compounding calorie tax, not a cliff.
29 September 2026
The HADEA API-stockpiling and rapid-dose-form tender closes. Its awards are the first bookable evidence that EU resilience procurement carries money, not just language.
The following overview summarizes the strategic building blocks, position directions, and allocated companies for this research theme.
Scale grocers and discounters with an owned agent, proprietary basket data, fulfilment density and audited retail media. Their ceiling is political: incrementality audits, trade-spend reclassification and margin-cap scrutiny.
Aseptic and medical-nutrition filling, sterile fill-finish, qualified APIs and protein processing. The barrier is the dossier, inspection history and permitted site, not the chemistry.
Physical route-to-market and pharmacy density remain valuable where informal or manual trade is losing share. Returns are currency-dependent and must be underwritten locally.
The primary trade is what not to own: step-fixed distribution, contested mid-tier brands, mass apparel, commodity export generics and injectable-only device exposure without a qualification node.
The defining shift is not that demand disappears—it does not. It is that the source of margin migrates. When intelligence becomes abundant and near-free, every rent that depended on an information gap compresses: the brand that existed as a mental shortcut, the category-management edge, the demand-sensing advantage, the trader’s data moat and the per-seat software licence. What survives is what abundant intelligence cannot manufacture: a licence, a permit, an audited qualification, physical route density and a relationship.
The repricing engine here is reclassification, not mean reversion, which is why it is glacial and then violent. The market still files these assets by their industry sticker while the underlying economics re-sort by moat type. That lag is the opportunity.
Consensus errs in two opposite ways. Bulls on the “Ozempic hits food” trade assume the volume tax is deep and imminent; sceptics assume poor adherence makes it negligible. Both miss the actual shape.
Persistence is genuinely poor and not improving—roughly a quarter discontinue by three months, a third by six, and over a third by twelve. The on-drug population is therefore not a cliff. But it is growing fast because price and access collapsed, not because people stay on longer: cheap orals, aggressive self-pay constructs, mandatory Medicare Part D formulary inclusion from 2027 and semaglutide generics already live in several large markets.
The result is a broad, shallow, compounding tax—on the order of 0.5–1.5% a year on indulgent calories and rather more on developed-market alcohol. Shallow is not safe. Direct-store-delivery and route-to-market networks are step-fixed. A cumulative 10–15% volume loss does not shave margins linearly; it breaks asset utilisation non-linearly into route consolidation, plant closures and impairments. The ordered hazard is predictable: rating-outlook cut, goodwill impairment, levered M&A, dividend cut and expulsion from quality and dividend-growth factor baskets.
The fashionable fear is that shopping agents become toll booths that tax every basket. The 2026 evidence points the other way. Retailer-owned assistants are being absorbed as features, monetised through existing margin and retail media, and kept to low-take plumbing by payment and platform rails. The only explicit agent take-rate visible—around 10–15%—is charged to external retailers that lack their own agent.
Agents therefore become a scale-consolidation force inside retail: own scale retailers with an owned agent and proprietary basket data; avoid sub-scale grocers that become tollable endpoints or acquisition targets. The binding ceiling on the grocer long is domestic politics and accounting, not Silicon Valley. Disclosing roughly 70%-margin retail media next to expensive food baskets invites margin-cap and windfall scrutiny, and part of that “media growth” may simply be reclassified trade promotion.
GLP-1 does not only subtract calories; it substitutes them. As calories get cheap, satiety, protein, fibre and micronutrient density become the scarce consumer good. The binding constraint is manufacturing: whey and casein fractionation, isolates, high-shear extrusion and, above all, regulatory-qualified aseptic and medical-nutrition filling lines.
Fermentation chemistry will very likely be commoditised by Chinese state-backed overcapacity around 2029–31, exactly as happened to vitamins, lysine and erythritol. The durable node is not the biology; it is the audited, inspected, customer-qualified line and the already-permitted brownfield site. Because those permits, grid connections and water rights are contested by data centres, the brownfield premium is structural rather than cyclical.
The honest opposing case deserves full strength. Mid-tier developed-market branded CPG may simply be cheap, and this whole dispersion construction may be a way of being clever instead of right.
On that path, a company at 13–15× with 4–6% EPS growth, a 3–4% yield, break-up optionality and a de-crowding tailwind beats a portfolio of half-discovered specialist longs whose re-rates are half duration anyway.
This complex has no clean sector tag and no dedicated ETF plumbing. You can be entirely right on the economics and watch the position sit still because passive money is not forced to own regulatory-qualified aseptic capacity. Meanwhile the crowded AI-and-defence trade can keep rising on momentum that has nothing to do with the thesis being wrong.
Agents can arbitrage brands away on price and specification, or entrench them through reorder defaults. The placement rent may accrue to the assistant, the retailer or be regulated toward zero. Hard data on agent-executed basket composition will settle the question.
If compute is nationalised as security infrastructure, the adjustment arrives through the bond market rather than a technology earnings bust. That delivers the de-crowding this thesis needs while denying the multiple expansion it wants.
This decides whether the grocer re-rate is an earnings-quality upgrade or an accounting illusion. The evidence is in CPG trade and advertising disclosure compared with retailer media growth.
| Rank | Layer | Rationale for margin capture |
|---|---|---|
| 1 | The Scale Demand Interface | Grocers and discounters with an owned agent, vertical private label, fulfilment density and audited retail media. Strengthened, not disintermediated, because payment rails deny the agent layer a rent position. The binding constraints are incrementality audits, trade-spend reclassification and margin-cap politics. Implied multiple: 13–17×, up from 10–14×. |
| 2 | Regulatory-Qualified Physical Capacity | Aseptic and medical or enteral filling, sterile fill-finish, customer-qualified API, protein fractionation and extrusion slots. The true GLP-1-era bottleneck is made scarcer by permit, grid and water competition with data centres. The moat is the dossier and inspection history, not the chemistry. |
| 3 | Sovereign-Contracted Essentials | Grain storage and milling, hospital generics and injectables, stockpiled APIs and protected nitrogen earn availability-fee or regulated-utility economics. This is a genuine upgrade from commodity treatment, but with an affordability ceiling and a coming supply wave of new listings. The move is one-time, from distressed 6–10× toward contracted 11–14×. |
| 4 | EM Branded Distribution and Dispensing | Physical route-to-market and pharmacy or store density beat digital discovery. These positions are owned through local listings and underwritten as currency exposures, with carry currencies preferred over translation-drag currencies. |
Structural losers are DSD- and route-levered mid-tier branded CPG, mainstream Western beer and mid-tier wine, mass apparel and mass retail without a qualification node, commodity export generics, peptide-only CDMOs and injectable device or glass businesses after oral scaling, midstream grain traders sold as compounders and per-seat horizontal software.
For the Human Basics research topic, the discussion among several models selected the following stocks as the more interesting positions. The ratings attached to each company come from Leeway’s general equity analysis and are independent of this research topic.
The Business-Rating scores the quality of the business model, independent of the share price. The Market-Fit-Rating tests eighteen fundamental figures for how well the company currently fits the market; a negative reading implies expected negative performance. The Cycle-Rating places the valuation in the stock’s own history: a higher figure means the shares are historically cheaper. The Leeway-Score combines the three in equal parts. How the ratings are calculated
From 19 August 2026 to 4 September 2026: Portfolio+3.2%ACWI+0.7%
Scale grocers and discounters with an owned agent, proprietary basket data, fulfilment density and audited retail media. Their ceiling is political: incrementality audits, trade-spend reclassification and margin-cap scrutiny.
Role in the Thesis: A trans-Atlantic grocery operator wielding a formidable private-label engine and a highly developed point-of-sale advertising infrastructure.
Valuation Context: The market fundamentally misprices the ownership of the customer interface. The consumer remains the grocer’s client, not the AI chatbot’s. The upside is driven by the market eventually reclassifying Ahold's high-margin retail media and private-label revenue streams away from low-growth retail multiples toward higher media/data comparables, underpinned by steady share buybacks.
Invalidation Risk: The thesis breaks if European or US regulators impose political margin caps on food staples, or if a severe price war crushes group EBIT margins. Furthermore, if retail media growth stalls—or if incrementality audits force consumer brands to slash their ad budgets—the re-rating narrative collapses. Note: A significant portion of any multiple expansion here is duration beta reliant on favorable rate movements, not just operational alpha.
Role in the Thesis: The dominant UK grocery platform, leveraging its massive Clubcard data ecosystem and private-label scale.
Valuation Context: Similar to Ahold, Tesco's structural value is anchored in its unyielding grip on the customer interface. The investment case hinges on the successful monetization of dunnhumby data and the expansion of its retail media network. Proving that these ad slots drive incremental sales rather than just cannibalizing existing trade spend is the catalyst to re-rate the business toward a mid-teens multiple.
Invalidation Risk: An aggressive, margin-crushing price war initiated by discounters such as Aldi or Asda, or direct government intervention capping food retail profits. The absolute growth profile is thin, and the stock carries the risk of languishing as a value trap if the media narrative fails to materialize cleanly in the bottom line.
Role in the Thesis: The undisputed customer interface across Mexico and Central America, structurally capturing market share from the informal trade sector.
Valuation Context: The protective moat is sheer physical store density. Returns here are driven by operational formalization and currency dynamics (MXN carry), rather than a standard US staples multiple expansion. For institutional portfolios, this is best utilized in a relative-value pair trade against vulnerable local DSD manufacturers to neutralize currency risk and isolate the retail-over-brand thesis.
Invalidation Risk: Mexican antitrust interventions that materially alter supplier dynamics, or a violent unwind of the MXN carry trade during a dollar liquidity squeeze. The valuation is not inherently cheap, and emerging-market assets are historically the first to be liquidated in a broader risk-off event.
Role in the Thesis: The essential background infrastructure, providing AI assistants, ad networks and delivery logistics for sub-scale grocers unable to build their own proprietary technology stacks.
Valuation Context: Instacart functions as a toll bridge within the grocery layer. The thesis wagers that AI-driven grocery shopping will integrate seamlessly into existing transaction and advertising rails. Smaller retailers will be forced to rent this capability, providing Instacart with a durable, high-beta revenue stream from the fragmented middle tier of the grocery market.
Invalidation Risk: Margin compression driven by aggressive pricing wars with Amazon or DoorDash, or the risk that large grocers successfully bring their technology and ad networks entirely in-house. Additionally, Instacart's ad revenues are highly dependent on the same CPG budgets currently facing intense incrementality scrutiny.
Aseptic and medical-nutrition filling, sterile fill-finish, qualified APIs and protein processing. The barrier is the dossier, inspection history and permitted site, not the chemistry.
Role in the Thesis: A critical European provider of qualified sterile fill-finish capacity and specialty heparin.
Valuation Context: The market currently misprices Rovi as a standard, cyclical CDMO. The thesis anticipates a structural reclassification of European sterile capacity into a security-of-supply infrastructure asset, driven by sovereign resilience mandates. The moat is the regulatory dossier and customer sign-off, which cannot be undercut by cheap overseas industrial parks.
Invalidation Risk: The European Critical Medicines Act (CMA) could pass as a toothless, unfunded mandate lacking price floors or local-content thresholds. Additionally, persistent underutilisation of fill-finish capacity into 2028 would drag heavily on earnings. The stock's low liquidity and concentrated customer base add inherent volatility.
Role in the Thesis: A unique staples player where the core structural value resides in its licensed medical and specialised nutrition divisions, rather than its traditional dairy or water segments.
Valuation Context: Danone is positioned as a rare beneficiary of the GLP-1 transition rather than a victim. The investment case requires the market to separate its high-protein and medical nutrition segments—which carry licences, reimbursement moats and high-single-digit compounding potential—from the broader, struggling branded CPG complex.
Invalidation Risk: Continued deterioration in the Chinese infant formula market, or the broader market's stubborn refusal to decouple Danone's valuation from traditional, slow-growth food peers. European margin-cap politics also poses a structural ceiling to profitability.
Role in the Thesis: A primary supplier of whey, isolates and sports nutrition operating strictly on customer-qualified production lines.
Valuation Context: This is a deep-value play on the physical scarcity of protein-ingredient processing. The true moat is the possession of permitted, grid-connected sites—which increasingly compete with data centres for power and water—rather than the consumer-facing brand on the protein tub.
Invalidation Risk: A collapse in whey pricing due to new global capacity coming online, or continued underperformance and management distraction from its branded consumer division. This is an optionality play that requires strict exit discipline if global protein capacity is visibly overbuilt by the end of the decade.
Physical route-to-market and pharmacy density remain valuable where informal or manual trade is losing share. Returns are currency-dependent and must be underwritten locally.
Role in the Thesis: The provider of mandatory logistics and customs compliance software underpinning global grocery and pharmaceutical supply chains.
Valuation Context: Descartes offers a dull, highly reliable rent at the border. The valuation is supported by the structural increase in global trade complexity. As resilience rules, tariffs and stockpile mandates multiply paperwork, Descartes benefits from per-transaction software monetisation, insulating it from the per-seat pricing pressure facing standard SaaS models.
Invalidation Risk: The emergence of AI agents capable of commoditising customs brokerage and classification workflows, or a severe macroeconomic contraction in global trade volumes. The premium multiple leaves zero margin for execution error.
The primary trade is what not to own: step-fixed distribution, contested mid-tier brands, mass apparel, commodity export generics and injectable-only device exposure without a qualification node.
Role in the Thesis: A traditional US branded food manufacturer heavily reliant on direct-to-store delivery (DSD) and highly exposed to the GLP-1 calorie reduction trend.
Valuation Context: The company faces flat-to-declining volumes while requiring increased marketing spend merely to defend a valuation that its growth no longer supports. The short thesis anticipates a cascading failure: rating downgrades, asset impairments, dividend cuts and ultimate expulsion from quality-factor baskets as step-fixed DSD costs non-linearly break operating margins.
Invalidation Risk: A strategic buyout or take-private transaction, or a stabilisation in volumes coupled with input-cost relief that secures the dividend. The stock is already optically cheap and carries a high dividend, making it an expensive, crowded short to maintain.
Role in the Thesis: A massive industrial bakery operating a highly dense, proprietary national delivery network.
Valuation Context: Bimbo is caught at the intersection of declining carbohydrate consumption and a rigid, step-fixed DSD cost base. The thesis projects that even a modest volume decline will render entire delivery routes uneconomic, forcing painful restructuring and impairments. The decline will print as a sudden step-down, not a gentle curve.
Invalidation Risk: Stabilisation in US bread volumes, aggressive family-led share buybacks or a broader consumer shift back toward carbohydrates. Robust Mexican operations could also mask US weakness for longer than anticipated, squeezing the short.
Role in the Thesis: A mass-market apparel retailer whose historical edge in trend-spotting and supply chain speed has been neutralised by technology.
Valuation Context: AI-driven design and hyper-fast competitors such as Shein and Temu have commoditised H&M's core advantage. The thesis argues there is no remaining scarcity node in its model—no unique brand equity, no proprietary data and no manufacturing moat—leaving it vulnerable to permanent margin compression.
Invalidation Risk: A successful internal turnaround that drives sustained gross-margin recovery, a robust consumer spending rebound in Europe or a take-private offer from the founding family.
Role in the Thesis: A manufacturer of commoditised export generics lacking the premium of regulatory-qualified, friend-shored capacity.
Valuation Context: Viatris competes almost entirely on price. The thesis identifies it as a structural loser in the shift toward sovereign supply-chain resilience, where governments will increasingly prioritise and fund local, qualified capacity over the absolute lowest-cost global volume.
Invalidation Risk: Successful pipeline execution, regulatory remediation or a break-up or acquisition scenario that unlocks sum-of-the-parts value. The stock's optically low valuation and high free-cash-flow yield mean any positive catalyst could trigger a violent short squeeze.
Role in the Thesis: A premier provider of injection systems and elastomers, currently priced for perpetual, uninterrupted growth in injectable weight-loss therapies.
Valuation Context: The market has extrapolated the current injectable GLP-1 boom indefinitely. The short thesis posits that the rapid scaling and collapsed pricing of oral small-molecule alternatives will severely undercut the projected volume growth for injectable devices, collapsing the stock's premium multiple.
Invalidation Risk: Injectable volumes continuing to outpace oral cannibalisation, or a surge in broader biologics demand that offsets GLP-1 device losses. The company boasts genuine quality moats, and being early on this transition carries significant mark-to-market risk.
| When | What happens | Why it matters |
|---|---|---|
| humanBasics.calendar.open | HADEA API-stockpiling and rapid-dose-form tender closes; awards are likely in the first half of 2027. | This is the first bookable evidence that EU resilience procurement carries money, not only political language. |
| humanBasics.calendar.open | US Medicare Part D 2027 formularies are finalised; GLP-1 inclusion becomes mandatory from 1 January 2027. | This is the largest step-change in the GLP-1 access function. |
| humanBasics.calendar.open | The first full oral-GLP-1 scanner quarters arrive in snacks, bakery, soft drinks and beer. | Systematic strategies can short exposed companies on the data release before management guidance changes. |
| humanBasics.calendar.open | European and Japanese grocers disclose retail media as a separate line. | The incrementality audit and trade-spend reclassification debate arrives in the same quarter and can stall the first re-rate attempt. |
| humanBasics.calendar.open | The final text and publication of the European Critical Medicines Act. | Funded price floors and local-content thresholds would turn a mandate into a real sovereign contract; their absence would leave only language. |
| humanBasics.calendar.open | External-agent take rates formalise at roughly 10–15% on third-party retailers. | This splits grocery into agent owners and agent tenants and drives consolidation. |
| humanBasics.calendar.open | Visible direct-store-delivery restructuring begins through route consolidation, plant closures and impairments. | The melting middle prints as a step-down once cumulative volume loss passes roughly 10–15% of utilisation. |
| humanBasics.calendar.open | Chinese synbio, amino-acid and enzyme export prices collapse while sovereign carve-outs and listings begin. | Fermentation chemistry becomes a commodity and the premium survives only on audited, customer-qualified and regulated lines. |
| humanBasics.calendar.open | Grid, water and permit decisions pit food, bio and aseptic plants against data centres. | Each denial raises the brownfield premium on already-permitted capacity. |
| humanBasics.calendar.open | European food-margin politics intensifies through price caps, margin controls or VAT actions. | This is the primary political ceiling on the grocer re-rate. |
| Path | Weight | What happens |
|---|---|---|
| Bull Case: The De-Crowding and the Re-Rate (20%) | 20% | AI-capex digestion or a credit accident breaks the momentum regime and real yields fall 150–250bp. After an initial funding-source drawdown, scale grocers move toward mid-teens on clean retail-media disclosure, funded resilience tenders reprice sterile and API small floats, qualified nutrition is reclassified as health-adjacent and break-ups mark up sum-of-parts. More than half the long-side return is still the rate move, not the structural work. |
| Base Case: Right on the Mechanism, Wrong on the Naive Vehicle (55%) | 55% | There is no aggregate re-rating. AI capex is sovereign-backed, the term premium grinds higher and real yields cap every low-growth multiple. Branded staples deliver carry only, while alcohol, mass apparel and commodity generics continue to de-rate. The payoff is dispersion and mostly negative selection: shorts and avoids do the work, while qualified-capacity and grocer longs deliver modest operating outperformance without full multiple expansion. |
| Bear Case: The Longs Fail with the Shorts (25%) | 25% | Real yields rise further, AI proves self-funding and keeps re-rating, and affordability politics arrives without a security-of-supply premium. Margin caps freeze the grocer re-rate as retail media is disclosed, incrementality audits expose much of it as reclassified trade spend, protein and aseptic capacity is over-built by 2029–30, and the resilience act passes as a mandate without money. Agents entrench incumbent brands, blunting the short leg. Only a handful of qualified-capacity positions hold. |
The assessment is produced in several steps. Independent model families answer the same question separately and then attack the results. What you read here has survived several rounds.
Any analysis can be wrong. That is why the falsification criteria and the counter-position sit on the same page as the thesis, not in the small print.
The numbers shown against individual companies do not come from this process. The Business-Rating scores business-model quality, the Market-Fit-Rating eighteen fundamental figures against the current market, the Cycle-Rating the valuation against the stock’s own history. They are documented under the Leeway scores.
The crowding out of the complex is real. The complex is not forgotten; it is re-priced for positive real yields and a contested end value. A revenue guarantee without pricing power is a bond. Bonds are paid for as bonds.
Because the assistant entrenches the grocer rather than replacing it, as long as payment and platform deny the assistant layer its own toll. Large grocers with private label and audited till advertising are the demand interface. The ceiling is politics, not technology.
Branded goods that still run their own van to the store, industrial bakery, mass beer, mass apparel, interchangeable generics, and devices priced only on the injectable curve. Most of the return in this assessment comes from what is left out.
Medicare takes the weight-loss drugs as mandatory. Together with tablets instead of only injections, the treated stock rises mechanically. Scanner data in snacks, bakery and beer should show that before the annual reports find the language.
No. Defence is not the position to avoid on any path. The base path is relative outperformance without a higher multiple, while AI investment stays fiscally backstopped. A digestion of AI spending or a credit event would be the favourable case, not the core.
Leeway separates business quality, fundamentals and timing. In this theme a company can be operationally solid and still deserve nothing better than a bond multiple. The ratings make that split visible instead of selling a sector beta.
Leeway scores business quality, fundamentals and timing separately and shows the reasoning. Try the linked grocery, nutrition and avoid-list companies for fourteen days, or read first how the ratings are built.
The data is recalculated on a weekly basis and depends on the current market value of the company and the balance sheet figures of the annual financial statements. The market value changes continuously with price changes, the balance sheets are created annually and change the valuation massively. The time of the annual financial statements and the metrics used can be viewed under "Metrics". Further information on how the analyses work can be found as tooltips directly on the analyses as well as in our explanations.
The information is intended to support you in your independent decision-making in implementing investment strategies and serves purely informational purposes. Past performance is not a reliable indication of future performance. No warranty can be given for the completeness, correctness and accuracy of the listed content. The information does not constitute specific investment recommendations. We neither know you nor your financial situation and do not provide investment advice. Only licensed investment advisors with knowledge of your personal circumstances may do this. PWP Leeway UG (limited liability) is not an investment advisor and does not collect any personal data for the purpose of investment optimization. PWP Leeway UG (limited liability) is a provider of investment recommendations and investment strategy recommendations. As such, it is registered with and supervised by the Federal Financial Supervisory Authority (BaFin). The legal notices on the use of the website and the General Terms and Conditions of PWP Leeway UG (limited liability) also apply.
All price data are closing prices of the respective stock exchanges. Price information and master data are provided by an external service provider. Furthermore, public trading data, such as provided by Finra.org, is used to analyze market behavior. No warranty can be given for the completeness, correctness and accuracy of the listed content.
